Pharmasset Further Refines Its Hepatitis C Polymerase Inhibitor
The Editors at Hepatitis Central
January 26, 2010
Print this page
An isomer of PSI -7851 (a polymerase inhibitor that has already demonstrated encouraging clinical results for Hepatitis C), Pharmasset believes that PSI-7977 would be more potent and better suited for manufacturing. Hence, Pharmasset has initiated a Phase 2a trial to test this substance on treatment naïve participants with Hepatitis C genotype 1.
Pharmasset Initiates Phase 2a Trial With PSI-7977, A Chirally Pure Isomer Of PSI-7851
Article Date: 23 Jan 2010
Pharmasset, Inc. (Nasdaq: VRUS) announces the initiation of a 28-day Phase 2a study with PSI-7977, a chirally pure isomer form of PSI-7851, a nucleotide analog polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV). The trial will evaluate various doses of PSI-7977 in combination with Pegasys (peginterferon alfa 2a) and Copegus (ribavirin) in patients with HCV genotype 1 who have not been treated previously.
Continue reading this entire article:
HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.